Scientists developed a mussel‑inspired bioadhesive patch that selectively targets and eliminates glioblastoma cells in preclinical models, offering a novel local therapeutic approach for an aggressive brain tumor. The device adheres to tumor surfaces, delivers cytotoxic payloads, and leverages bioadhesive chemistry to improve retention and focal delivery during surgical resection. The platform could change intraoperative strategies for glioblastoma by combining physical adhesion with targeted cell killing; next steps include safety profiling, dosing optimization, and scaled animal studies before clinical translation. If validated, the patch may provide a complementary option to systemic therapies and radiotherapy in localized control of residual disease.